OTCMKTS:AOLS

Aeolus Pharmaceuticals Competitors

$0.0061
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.00
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.02
Volume237,506 shs
Average Volume683,546 shs
Market Capitalization$927,749.00
P/E RatioN/A
Dividend YieldN/A
Beta2.38

Competitors

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Vs. AKRXQ, VGLS, RSPI, IMNPQ, INNVD, and NSPX

Should you be buying AOLS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aeolus Pharmaceuticals, including Akorn (AKRXQ), VG Life Sciences (VGLS), RespireRx Pharmaceuticals (RSPI), Immune Pharmaceuticals (IMNPQ), Innovus Pharmaceuticals (INNVD), and Inspyr Therapeutics (NSPX).

Akorn (OTCMKTS:AKRXQ) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Akorn and Aeolus Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A

Aeolus Pharmaceuticals has lower revenue, but higher earnings than Akorn.

Institutional and Insider Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by insiders. Comparatively, 66.6% of Aeolus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Akorn and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
Aeolus PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Akorn and Aeolus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Aeolus Pharmaceuticals0000N/A

Volatility and Risk

Akorn has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500.

Summary

Aeolus Pharmaceuticals beats Akorn on 5 of the 7 factors compared between the two stocks.

VG Life Sciences (OTCMKTS:VGLS) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for VG Life Sciences and Aeolus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VG Life Sciences0000N/A
Aeolus Pharmaceuticals0000N/A

Volatility and Risk

VG Life Sciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500.

Profitability

This table compares VG Life Sciences and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VG Life SciencesN/AN/AN/A
Aeolus PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares VG Life Sciences and Aeolus Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VG Life SciencesN/AN/AN/AN/AN/A
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Aeolus Pharmaceuticals beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Volatility and Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for RespireRx Pharmaceuticals and Aeolus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RespireRx Pharmaceuticals0000N/A
Aeolus Pharmaceuticals0000N/A

Profitability

This table compares RespireRx Pharmaceuticals and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RespireRx PharmaceuticalsN/AN/A-3,387.16%
Aeolus PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares RespireRx Pharmaceuticals and Aeolus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Aeolus Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Aeolus Pharmaceuticals and Immune Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeolus Pharmaceuticals0000N/A
Immune Pharmaceuticals0000N/A

Profitability

This table compares Aeolus Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeolus PharmaceuticalsN/AN/AN/A
Immune PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Aeolus Pharmaceuticals and Immune Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A
Immune PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Aeolus Pharmaceuticals beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Profitability

This table compares Aeolus Pharmaceuticals and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeolus PharmaceuticalsN/AN/AN/A
Innovus Pharmaceuticals-34.51%-682.54%-78.57%

Valuation and Earnings

This table compares Aeolus Pharmaceuticals and Innovus Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A
Innovus Pharmaceuticals$23.99 million0.00$-8,280,000.00($4.16)N/A

Aeolus Pharmaceuticals has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent recommendations for Aeolus Pharmaceuticals and Innovus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeolus Pharmaceuticals0000N/A
Innovus Pharmaceuticals0000N/A

Insider and Institutional Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 66.6% of Aeolus Pharmaceuticals shares are held by insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aeolus Pharmaceuticals beats Innovus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Earnings & Valuation

This table compares Aeolus Pharmaceuticals and Inspyr Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

Profitability

This table compares Aeolus Pharmaceuticals and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeolus PharmaceuticalsN/AN/AN/A
Inspyr TherapeuticsN/AN/A-298.11%

Risk & Volatility

Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Aeolus Pharmaceuticals and Inspyr Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeolus Pharmaceuticals0000N/A
Inspyr Therapeutics0000N/A

Summary

Aeolus Pharmaceuticals beats Inspyr Therapeutics on 2 of the 2 factors compared between the two stocks.


Aeolus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.45 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$3.00 millionN/A-0.09
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.94 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.02flat$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.22 million$20,000.00-1.00
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48flat$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03flat$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48flat$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.10flat$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22flat$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03flat$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.02flat$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00flat$678,000.00N/A0.00Increase in Short Interest
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15flat$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02flat$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.